Analyst consensus rating
Connect Biopharma Holdings Analyst Rating: Strong Buy
CNTB is rated Strong Buy by 8 analysts with a $7.25 target. As of 2026-08-25.
Direct answer
Connect Biopharma Holdings's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.25.
Forecast evidence checked August 25, 2026.
Get free Connect Biopharma Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.30
- Average price target
- $7.25
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +73.9%
- Target upside
- +215.2%
- High target gap
- +334.8%
- Target range width
- 260.9%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Connect Biopharma Holdings?
Connect Biopharma Holdings has a verified Strong Buy consensus. The same dataset has an average price target of $7.25.
How far are Connect Biopharma Holdings's low and high targets from the recorded price?
The low target implies +73.9%, while the high target implies +334.8%.
How many analysts are included in Connect Biopharma Holdings's consensus?
The verified consensus includes 8 analysts.
How is Connect Biopharma Holdings's target upside or downside calculated?
The average target of $7.25 is divided by the recorded price of $2.30, then one is subtracted to produce +215.2%. This does not guarantee a future return.
When was Connect Biopharma Holdings's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.